Veterans Benefits Administration awards medical disability examination services contract to Leidos QTC Health Services

RESTON, Va., Jan. 6, 2025 /PRNewswire/ — Leidos (NYSE:LDOS) today announced that its wholly owned subsidiary, QTC Medical Services, operating under the brand name Leidos QTC Health Services, has been awarded a contract by the Veterans Benefits Administration (VBA) for performing Medical Disability Examination Services in Regions 1-4.  

“With more than 1 million examination cases delivered in 2024, Leidos QTC Health Services continues to drive innovation and increase program efficiency for the VBA,” said Liz Porter, Leidos Health & Civil Sector president. “These veteran disability compensation and pension exams provide a vital service to those who have sacrificed so much for our nation.”

Leidos QTC Health Services has supported the VBA continually since 1998, expanding services to an average of 63,000 veterans per month. Continuous innovations have generated far greater program efficiency, including infusing artificial intelligence and machine learning to augment processing.

Leidos QTC Health Services also expanded its fleet of mobile health clinics to provide better access to services for veterans in rural locations and for those who are homebound. These and other program improvements are allowing the VBA to provide smarter, more effective exam services for veterans.

Under the new short-term indefinite delivery/indefinite quantity (IDIQ) contract, Leidos will provide the exams and associated case administration services nationwide, including claimant communication, appointment scheduling, provider training, system interfaces with VBA IT systems, and medical records management. With a period of performance of one year and one optional year, the contract includes performance-based measures of exam production, average days to complete, average days pending, quality of service, and customer satisfaction evaluations.

About Leidos

Leidos is an industry and technology leader serving government and commercial customers with smarter, more efficient digital and mission innovations. Headquartered in Reston, Virginia, with 48,000 global employees, Leidos reported annual revenues of approximately $15.4 billion for the fiscal year ended December 29, 2023. For more information, visit www.leidos.com

Certain statements in this announcement constitute “forward-looking statements” within the meaning of the rules and regulations of the U.S. Securities and Exchange Commission (SEC). These statements are based on management’s current beliefs and expectations and are subject to significant risks and uncertainties. These statements are not guarantees of future results or occurrences. A number of factors could cause our actual results, performance, achievements, or industry results to be different from the results, performance, or achievements expressed or implied by such forward-looking statements. These factors include, but are not limited to, the “Risk Factors” set forth in Leidos’ Annual Report on Form 10-K for the fiscal year ended December 29, 2023, and other such filings that Leidos makes with the SEC from time to time. Readers are cautioned not to place undue reliance on such forward-looking statements, which speak only as of the date hereof. Leidos does not undertake to update forward-looking statements to reflect the impact of circumstances or events that arise after the date the forward-looking statements were made.

Contact:

Alyssa Pettus
(571) 526-6743
alyssa.t.pettus@leidos.com

Brandon Ver Velde
(571) 526-6257
brandon.p.vervelde@leidos.com  

 

View original content to download multimedia:https://www.prnewswire.com/news-releases/veterans-benefits-administration-awards-medical-disability-examination-services-contract-to-leidos-qtc-health-services-302342711.html

SOURCE Leidos Holdings, Inc.

Staff

Recent Posts

Red Light Holland’s Partner FDA-Compliant and DEA-Registered Irvine Labs Receives 2025 Psilocybin DEA Quotas, Including Import Quota

The companies are now moving forward with the import permit application process.Following expected approval of…

27 minutes ago

Psyence BioMed Announces USD$500,000 Follow-On Investment in PsyLabs and Global Ibogaine Supply Agreement

New York, New York--(Newsfile Corp. - April 15, 2025) - Psyence Biomedical Ltd. (NASDAQ: PBM)…

27 minutes ago

Ezra Appoints Dr. Danna Chung as Chief Medical Officer

Dr. Chung brings expertise in scaling medical teams to Ezra’s mission of making early cancer…

27 minutes ago

NeurAxis to Present at the Planet MicroCap Showcase: VEGAS in partnership with MicroCapClub on Wednesday, April 23, 2025 & 1×1 Meetings on Thursday, April 24, 2025

CARMEL, Ind., April 15, 2025 (GLOBE NEWSWIRE) -- NeurAxis, Inc. (“NeurAxis,” or the “Company”) (NYSE…

28 minutes ago

LiveWorld Releases First-Ever AI Brand Reputation Index for Leading Pharmaceutical Brands

Study Highlights Critical Influence of AI-Driven Reputation on Pharma Market Leaders and New EntrantsCAMPBELL, Calif.…

28 minutes ago